A new trial to test whether ibuprofen could reduce breathing problems associated with coronavirus is due to start. Scientists will look into whether a special formulation of the common drug could reduce the serious side effect seen in Covid-19 patients.
If the formulation is seen to reduce respiratory problems, it could potentially lead to shorter hospital stays and fewer patients needing help in intensive care units.
Only hospitalised patients will be involved in the study – not those who have only mild or suspected Covid-19. Mitul Mehta, professor of neuroimaging and psychopharmacology and director of Centre for Innovative Therapeutics at Kings College London, told the PA news agency: “It’s a trial for patients with Covid-19 disease to